The clinical-stage biopharma Athira Pharma (Nasdaq:ATHA) has published a review paper stressing the need for new treatments for Alzheimer’s disease.
The paper also states that one of its small molecule drugs, fosgonimeton, holds potential for treating Alzheimer’s.
The Journal of Alzheimer’s Disease published the paper titled “The Case for a Novel Therapeutic Approach to Dementia: Small Molecule Hepatocyte Growth Factor (HGF/MET) Positive Modulators.”
ATHA shares were down 1.24% to $3.99 in pre-market trading.
Moving beyond ACT-ADIn June 2022, Athira Pharma revealed disappointing results from the Phase 2 ACT-AD trial focused on Alzheimer’s disease. The study did not show a statistically significant change in ERP P300 latency (a measure of cognitive function) for the modified intent-to-treat population. Fosgonimeton recipients were divided into 40 mg and 70 mg dose groups. Investigators performed a pooled analysi…